Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alirocumab (ALI) Compassionate Use Program Providing Early Access to Alirocumab (ALI) Prior to its Commercial Availability to Patients with Severe Heterozygous Familial Hypercholesterolaemia and/or High-Risk Patients (LDL-C ≥160 mg/dL ) Not Controlled with Maximal Tolerated Dose (MTD) of Standard of Care Lipid-Lowering Therapy (LLT)

Trial Profile

Alirocumab (ALI) Compassionate Use Program Providing Early Access to Alirocumab (ALI) Prior to its Commercial Availability to Patients with Severe Heterozygous Familial Hypercholesterolaemia and/or High-Risk Patients (LDL-C ≥160 mg/dL ) Not Controlled with Maximal Tolerated Dose (MTD) of Standard of Care Lipid-Lowering Therapy (LLT)

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Alirocumab (Primary)
  • Indications Hyperlipoproteinaemia type IIa
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Most Recent Events

    • 17 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top